# Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)

> **NCT07527819** · — · NOT_YET_RECRUITING · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 75 (estimated)

## Conditions studied

- Triple Negative Breast Cancer (TNBC)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07527819
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-08
- **Primary completion:** 2031-04
- **Final completion:** 2031-12-31
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07527819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07527819, "Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07527819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*